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IntroductIon Ulcerative colitis (UC), Crohn’s 
disease (CD) and indeterminate colitis are de‑
fined by a common term of inflammatory bow‑
el disease (IBD). These diseases have common 
complex and multifactorial pathogenesis. It is 
currently accepted that genetic, environmental 
and immuno logical factors contribute to devel‑
opment of IBD.1,2 IBD involves disorders of nu‑
merous immuno logical mechanisms associated 
with cellular and humoral immune response. It 
is believed that in CD, the cellular response, with 
increased activation of CD4 + T helper (Th) cells 
mostly differentiated into Th1 subpopulation, is 
of great significance. This lymphocyte population 
produces increased amounts of cytokines, which 
have a significant impact on the further course 
of the immune response. Predominant cytok‑
ines in CD are tumor necrosis factor‑α (TNF‑α), 
inter feron‑γ (INF‑γ) and inter leukins 1β (IL‑1β), 
IL‑2, IL‑6, IL‑8 and IL‑12. UC involves increased 
expression of Th2 cells engaged in the humor‑
al response, what is associated with produc‑
tion of inter leukin 4 (IL‑4), IL‑5, IL‑6, IL‑10 and 
TNFα.3‑5 In IBD pathogenesis, the imbalance be‑
tween pro‑inflammatory cytokines (IL‑1, IL‑1β, 
IL‑2, IL‑6, IL‑8, IL‑12, IL‑17, IL‑23, TNF‑α, INF‑γ) 
and anti‑inflammatory cytokines (IL‑4, IL‑10, 
IL‑11, IL‑13) is also important. In recent studies 
performed in the murine model using monoclo‑
nal antibodies, attention was also paid to IL‑17 
and IL‑23. It leads to the conclusion that these 
cytokines have a relevant function in the patho‑
genesis of UC and CD.6
An important phenomenon in the inflamma‑
tory process of IBD is an increased expression 
of endothelial leukocyte adhesion molecule 1 
(ELAM‑1) and inter cellular adhesion molecule 1 
(ICAM‑1) on the surface of endothelial cell mem‑
branes. The increased expression of those adhe‑
sion molecules on capillary endothelium results 
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AbstrAct
Ulcerative colitis (UC), Crohn’s disease (CD) and indeterminate colitis are defined as inflammatory 
bowel diseases (IBD). Those diseases involve disorders of numerous immuno logical mechanisms 
associated with cellular and humoral immune response. In CD cellular response is considered to be 
of crucial importance, and dominant cytokines include: tumor necrosis factor α (TNF‑α), inter feron γ 
(INF‑γ) and inter leukins 1β (IL‑1β), IL‑2, IL‑6, IL‑8, IL‑12. In UC, increased expression of Th2 (respon‑
sible for humoral response) is observed. It is connected with increased production of inter leukins: 
4 (IL‑4), IL‑5, IL‑6, IL‑10 and TNF‑α. Lack of balance between pro‑inflammatory and anti‑inflammatory 
cytokines is of vital importance in pathogenesis of IBD. Conventional therapy of CD and UC quite 
commonly fails to bring satisfactory results, therefore an inter est in new therapeutic options, that 
is, bio logical therapy, gene therapy, hematopoietic stem cell transplantation, and leucapheresis, 
has aroused recently. Bio logical therapy is focused on different stages of the inflammatory process. 
The fundamentals of bio logical strategy involve neutralization of pro‑inflammatory cytokines, use 
of anti‑inflammatory cytokines and inhibition of neutrophil adhesion. Bio logical therapy is a promising 
option because it enables to withdraw corticosteroids and immunosuppressive agents or to reduce 
their dose. Moreover, it shortens the hospital stay, allows to avoid surgical procedures, extends 
the remission period and improves patients’ quality of life. Currently, 2 agents, infliximab and adali‑
mumab, are registered for the bio logical therapy of CD in Poland.
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infections, a history of malignant disease or ac‑
tive cancer, significant immunization observed 
prior to the disease onset, demyelinating diseases, 
and moderate to severe cardiac insufficiency (New 
York Heart Association [NYHA] class III/IV).
Bio logical therapy could not be initiated in pa‑
tients with active (including chronic or local) in‑
fection, until the infection has been successfully 
treated. Before the initiation of the therapy, all 
patients should be examined in order to exclude 
both active and inactive (latent) infections. If la‑
tent tuberculosis is diagnosed before the initia‑
tion of bio logical therapy, appropriate prophylax‑
is should be implemented. In such cases, possible 
benefits of bio logical therapy should be careful‑
ly reassessed. Diagnostic evaluation of hepatitis 
should also be made before treatment initiation. 
Clinical trials using TNF‑α antagonists demon‑
strated hepatitis reactivation in patients with 
chronic hepatitis B virus (HBV) infection. HBV 
carriers, who require bio logical therapy, should 
be carefully monitored throughout the whole pe‑
riod of therapy and several months afterwards. 
If HBV infection reactivates, bio logical thera‑
py should be discontinued and antiviral therapy, 
e.g. with lamivudin or entacavir, should be intro‑
duced. Currently, there is no sufficient data con‑
cerning treatment of HBV carriers with antiviral 
agents combined with TNF‑α antagonists, to pre‑
vent HBV reactivation. Likewise, there is no evi‑
dence regarding secondary transmission of infec‑
tion with live vaccines in patients receiving bio‑
logical agents; therefore, this group of patients 
may simultaneously receive vaccines, excluding 
live vaccines.
Bio logical therapy should be discontinued 
in patients with heart failure NYHA class I/II 
who demonstrated new symptoms or whose car‑
diac insufficiency symptoms worsened. Particu‑
lar precautions should also be taken in bio logical 
therapy in patients with chronic obstructive pul‑
monary disease and with demyelinating disorders 
of the central nervous system.
Controlled clinical trials on TNF‑α blockers 
showed higher prevalence of lymphomas in pa‑
tients receiving anti‑TNF‑α antibodies as com‑
pared to the control group. However, the prev‑
alence was low and the follow‑up period for pa‑
tients receiving placebo was shorter than for pa‑
tients undergoing bio logical therapy. According 
to the current opinions, a risk of lymphoma or 
other type of cancer cannot be excluded in pa‑
tients receiving anti‑TNF‑α antibodies. Based 
on currently available evidence, it is not yet clear 
whether TNF‑α blockers influence the risk of mu‑
cous membrane dysplasia and colorectal cancer. 
Therefore, in patients with newly diagnosed dys‑
plasia of colon mucosa undergoing bio logical ther‑
apy, risks and benefits for each patient should be 
thoroughly assessed and therapy cessation should 
be considered.
Bio logical therapy is not recommend‑
ed in pregnant women. Clinical experience is 
too limited to exclude the risk of an adverse 
in a higher number of plasmocytes, lymphocytes, 
macrophages and neutrophils within the inflamed 
tissue.
Bio logical therapy is a type of treatment aimed 
at various stages of the inflammatory process. Ba‑
sic directions of bio logical therapy involve neu‑
tralization of pro‑inflammatory cytokines, use 
of anti‑inflammatory cytokines and inhibition 
of neutrophil adhesion.7,8 Currently, infliximab 
and adalimumab are 2 bio logical drugs licensed 
for CD therapy in Poland. Other preparations 
are currently tested in clinical trials and are not 
routinely used in IBD therapy; however, they in‑
clude preparations licensed for therapy of other 
disorders, for example rheumatoid arthritis or 
multiple sclerosis.
Indications for bio logical therapy in inflammatory 
bowel disease Indications for bio logical thera‑
py in CD are as follows:
1 induction therapy in patients with moderate 
or severe disease activity who do not respond 
to conventional treatment with 5‑ASA prepara‑
tions, glucocorticosteroids and/or immunosup‑
pressive agents
2 induction therapy in patients with fistulas, 
present despite appropriate standard therapy 
(antibiotic therapy, immunosuppression, surgi‑
cal drainage)
3 maintenance treatment in patients who re‑
sponded to the induction therapy.
In UC, bio logical therapy is recommended as 
induction therapy in patients with active UC who 
did not respond to standard treatment (5‑ASA 
preparations, glucocorticosteroids, immuno‑
suppressive agents), and as maintenance treat‑
ment in patients who responded to induction 
therapy.
The former IBD treatment algorithm, used for 
several years, is based on a “step‑up” strategy that 
involves a gradual enhancement of the therapy 
by adding glucocorticosteroids to 5‑ASA prepa‑
rations and, with no improvement, an immuno‑
suppressive agent, and only ultimately a bio logical 
drug.9 Currently, a “top‑down” strategy, in which 
IBD treatment is initiated with a bio logical drug, 
is recommended still more commonly.10
Clinical trials aiming at assessment of effica‑
cy and safety of bio logical therapy of duration 
of several years and also the “top‑down” method 
in IBD are still being used. Doubts about the du‑
ration of bio logical therapy with the “top‑down” 
strategy are associated with increased risk of ad‑
verse events.11,12
Despite numerous trials focusing on bio logical 
therapy, duration of maintenance therapy has not 
been determined to date, but, as the trial analy‑
sis shows, it may last up to one year.13
contraindications for bio logical therapy in inflam‑
matory bowel disease Contraindications for bio‑
logical therapy are hypersensitivity to the active 
or any ancillary agent, active tuberculosis or oth‑
er severe infections, like sepsis and opportunistic 
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production of cell adhesion molecules (e.g. ICAM, 
ELAM, integrins) by endothelial cells, leading 
to increased penetration of lymphocytes, mac‑
rophages and neutrophils from the circulation 
into inflamed tissues, angiogenesis, fibroblast 
proliferation, development of granulomas and in‑
creased prothrombic activity. TNF‑α stimulates 
production of platelet activating factor (PAF) and 
IL‑8 by endothelial cells and induces local produc‑
tion of leukotriene B4.
14,15 Stimulation of the pro‑
duction and secretion of IL‑1 and IL‑6 influences 
the development of acute phase reaction with re‑
lease of C‑reactive protein (CRP) and with such 
symptoms as fever, anemia, thrombocytopenia, 
leukocytosis, weight loss. TNF‑α is also respon‑
sible for evoking pain by increasing sensitivity 
of nociceptors to prostaglandins.
bio logical agents licensed for inflammatory bow‑
el diseases treatment Infliximab Is a chimeric 
human/murine monoclonal IgG1 antibody, bind‑
ing with high affinity both to the soluble and 
the transmembrane form of human TNF‑α, how‑
ever does not neutralize the lymphotoxin form 
(TNF‑β). Infliximab quickly forms stable complex‑
es with human TNF‑α. This is tantamount to loss 
of bio logical activity by TNF‑α.
The drug is administered in 5 mg/kg doses 
by 2‑hour intravenous infusion. Induction ther‑
apy in 3 doses is recommended, following the al‑
gorithm of week 0, 2 and 6, and for sustaining 
the remission in a dose repeated every 8 weeks. 
Available evidence does not justify further inflix‑
imab therapy in patients who have failed to re‑
spond to induction therapy.16,17
Adalimumab is a recombinant human monoclo‑
nal antibody obtained by expression in Chinese 
hamster ovary cells. Adalimumab is a fully human 
immunoglobulin G1. It specifically binds to TNF‑α 
and neutralizes its bio logical function, blocking 
TNF‑α inter action with p55 and p75 receptors 
on the cell surface. It also modulates the bio logical 
response, induced and regulated by TNF‑α, that 
involves among others in altered levels of inter‑
cellular adhesion molecules responsible for leu‑
kocyte migration (ELAM‑1, ICAM‑1, vascular cell 
adhesion molecule‑1 [VCAM‑1]).
The drug is administered in induction ther‑
apy in a dose of 80 mg by subcutaneous injec‑
tion, and then 40 mg in week 2. If a quick re‑
sponse to treatment is required, higher doses 
could be administered, i.e. 160 mg a week (a dose 
could be administered as 4 injections during 
24 h or 2 injections daily during 2 subsequent 
days), and then 80 mg in week 2. In order to sus‑
tain the remission, 40 mg is administered every 
second week. Clinical trials showed that in pa‑
tients who did not respond to treatment within 
4 weeks, continuation of maintenance treatment 
up to week 12 inclusive may be beneficial. In pa‑
tients who do not respond to treatment within 
that time, continuation of such treatment should 
be reconsidered.18,19
effect of anti‑TNF‑α antibodies on an appro‑
priate immune response in newborns. Patients 
in child‑bearing age undergoing bio logical therapy 
are recommended to take contraceptives through‑
out the therapy period and up to 6 months after‑
wards. Bio logical therapy is also not recommend‑
ed during breastfeeding.
Adverse effects in bio logical therapy The most 
common adverse effects during bio logical thera‑
py are as follows:
1 acute and delayed transfusion reactions
2 delayed reactions, like serum disease
3 lupus‑like syndrome
4 reactivation tuberculosis
5 bacterial and fungal infections (aspergillosis, 
histoplasmosis, cryptococcosis, candidosis, list‑
eriosis, pneumocystosis)
6 increased activity of liver enzymes
7 cardiovascular insufficiency
8 development of cancer – lymphomas (rare)
9 mortality similar to untreated patients.
Prevalence and types of adverse events are as‑
sociated with development of antibodies against 
TNF‑α blockers. For infliximab, this phenomenon 
is observed in 6–13% of patients and for adali‑
mumab only in 2.6%. It has been found that si‑
multaneous use of immunosuppressive agents 
(azathioprine, 6‑mercaptopurine) or methotrex‑
ate blocks the synthesis of anti‑infliximab and an‑
ti‑adalimumab antibodies.
role of tumor necrosis factor‑α in the inflammatory 
process TNF‑α is produced mainly by mono‑
cytes and macrophages, and to a lesser extent 
by neutrophils, keratinocytes, fibroblasts and 
mastocytes. Factors stimulating TNF‑α secre‑
tion include endotoxins, antigens and osmotic 
stress. Production and release of TNF‑α are stim‑
ulated, among others, by INF‑γ and IL‑1. Physio‑
logically, TNF‑α occurs in 2 forms: as a precur‑
sor, 26 kDa transmembrane protein and the sol‑
uble (free) form of molecular mass of 17 kDa. 
The soluble form is responsible for most of bio‑
logical functions of TNF‑α, while the transmem‑
brane form is active in processes, like apoptosis, 
cell proliferation, activation of B lymphocytes, 
or inflammation.
There are 2 types of receptors for TNF‑α: type 1 
(p55 protein) and type 2 (p75 protein) of mo‑
lecular mass 55 kDa and 75 kDa, respectively. 
They differ in the glycosylation degree and affin‑
ity to TNF‑α, therefore, they may transmit dif‑
ferent signals to the cell.
TNF‑α triggers a cascade of pro‑inflammato‑
ry reactions stimulating production of numerous 
cytokines and has significance both in induction 
of the inflammatory process and its sustaining. 
It is a main cytokine involved in the pathomech‑
anism of auto immune diseases, transplant re‑
jection and septic shock. At the molecular lev‑
el, it activates a nuclear factor responsible for 
control of transcription of pro‑inflammatory cy‑
tokine genes. At the tissue level, TNF‑α stimulates 
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group. The drug was found well tolerated but in‑
effective in glucocorticosteroid dose reduction 
in steroid‑dependent CD patients.27
Comparison of the trials using CDP 571 and 
infliximab found that CDP‑571 was a safe med‑
ication, but not as effective in CD as infliximab. 
Therefore, further clinical trials on CDP 571 in this 
disease were discontinued.
certolizumab pegol (cdP 870) Is a monoclonal 
antibody, combining the Fab fragment of human 
anti‑TNF‑α antibody with polyethylene glycol. 
The combination with polyethylene glycol result‑
ed in prolonged serum half‑life to approximately 
2 weeks, which permits less frequent dosage.
In the completed Phase II clinical trials, 
CDP 870 was used in doses of 100, 200, 400 mg 
administered subcutaneously each 4 weeks. Af‑
ter 12 weeks clinical improvement was observed 
in 29.7%, 30.6% and 33.3% of the patients, re‑
spectively, and in 15.1% of the patients in the pla‑
cebo group.28 It was also shown that clinical re‑
sponse was more favorable in patients receiv‑
ing certulizumab in doses of 400 mg, in whom 
CRP levels were above 10 mg/l.29,30 More favor‑
able clinical response in induction of the remis‑
sion was observed in the trials in which doses 
of 400 mg CDP870 were additionally adminis‑
tered in week 2.31 It was also demonstrated that 
Certolizumab may be effective in treatment of ac‑
tive CD patients who were refractory to inflix‑
imab therapy.32
In Poland and other countries, certolizumab 
has not been licensed yet. Phase III of PRECISE 
trials is still under way.
Golimumab (cnto 148) Is a human monoclonal 
anti‑TNF‑α antibody. In the published phase III 
clinical trials, CNTO 148 was administered sub‑
cutaneously in doses of 50 mg or 100 mg every 2 
or 4 weeks in patients with rheumatoid arthritis. 
Golimumab was found well tolerated and effective 
in patients who suboptimaly responded to meth‑
otrexate monotherapy.33 Centocor phase III clin‑
ical trials using golimumab every 4 weeks in sub‑
cutaneous doses of 50 mg, 100 mg and 200 mg 
in patients with moderate and severe exacerba‑
tion of UC are currently underway.
Bio logical therapy also involves pro‑inflamma‑
tory inter leukin antibodies, like daclizumab, basi‑
liximab (anti‑IL‑2 antibodies), atlizumab, tocili‑
zumab (anti‑IL‑6 receptor antibodies), or antibod‑
ies against IL‑12, IL‑17 and IL‑23. Attempts are 
also made to administer anti‑inflammatory inter‑
leukins, including recombinant IL‑10 and IL‑11. 
Clinical trials are also conducted using antibod‑
ies against INF‑γ (fontolizumab), α4β7‑integrin 
(MLN‑02), α4‑integrin (natalizumab), CD3 lym‑
phocytes (visilizumab), and alicaforsen (ISIS‑2302 
– antisense oligonucleotide against ICAM‑1 that 
inhibits migration of monocytes and granulo‑
cytes to the inflammatory site).
Another direction of bio logical therapy in clin‑
ical trials is focused on the use of growth factors. 
bio logical agents licensed for other disorders or un‑
dergoing clinical trials Etanercept Is a genetical‑
ly modified human protein made by combining 2 
ligands of human p75 TNF‑α receptor with the Fc 
region of human immunoglobulin G1. Etanercept 
binds 2 TNF‑α molecules, acting as a “false” recep‑
tor, and, in contrast with infliximab, it also neu‑
tralizes the TNF lymphotoxin form TNF‑β.
Clinical trials involved 25 mg doses subcutane‑
ously, twice a week, in patients with active CD for 
12 weeks. Clinical and endoscopic improvement 
was achieved in about 50% of the patients, but it 
has lasted on average for approximately 3 weeks 
since the drug was withdrawn. It may result both 
from short half‑life of the medication (68 ±12h), 
and from the fact that etanercept blocks only 
circulating forms of TNF‑α.20,21 Etanercept is li‑
censed for treatment of active rheumatoid arthri‑
tis, psoriatic arthritis, juvenile idiopathic arthri‑
tis and ankylosing spondylitis.
onercept Is a recombined form of human sol‑
uble p55 TNF receptor. A study by Rutgeerts 
et al. involved 207 patients with active CD who 
were receiving onercept subcutaneously in sever‑
al different doses or placebo 3 times a week for 
8 weeks. After 8 weeks, remission was achieved 
in 23.5% of the patients in the placebo group and 
in 34.8%, 20.0%, 26.1%, and 28.6% of the pa‑
tients in the groups receiving onercept (10 mg, 
25 mg, 35 mg and 50 mg doses, respectively).22 
Other completed randomized placebo‑controlled 
trials demonstrated good tolerance of onercept, 
but its lower effectiveness in patients with active 
CD in comparison with infliximab, adalimumab 
or certolizumab pegol.23,24
CDP 571 (Humicade) is a humanized, mono‑
clonal anti‑TNF‑α IgG4 antibody, made in 95% 
of human immunoglobulin and in 5% of murine 
protein. CDP 571 neutralizes both the soluble 
and membrane forms of human TNF‑α. Clin‑
ical trials using CDP 571 in CD were initiated 
simultaneously with the trials with infliximab 
were published in 1997. The trials showed effec‑
tiveness of CDP 571 in induction of the disease 
remission and its good tolerance.25 In 2004, re‑
sults of the trial performed in the Mayo Clin‑
ic were published. This trial involved CDP 571 
in 10 mg/kg doses infused intravenously, each 
8th week during 24 weeks in active CD patients. 
Clinical response was assessed in weeks 2 and 28. 
In week 2, clinical response was achieved in 49.5% 
(the group receiving CDP 571), and in the placebo 
group in 15.5% of the patients, whereas in week 
28, in 28.7% and 12.1% of the patients, respec‑
tively. It was found that CPD571 was effective 
in inducing only a short remission so it could 
not be used in a long‑term therapy.26 In clinical 
trials on steroid‑dependent CD patients, with 
Crohn’s disease activity index ≤150, CDP517 was 
used in 10 mg/kg intravenous doses, once every 8 
weeks during 36 weeks. Glycocorticosteroid dose 
reduction was possible in 29.3% of the patients 
treated with CDP517 and in 36.7% in the placebo 
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tenance of clinical response and remission in patients with Crohn’s dis‑
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ology. 2001; 121: 1088‑1094.
22 Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate 
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trial. Clin Gastroenterol Hepatol. 2006; 4: 888‑893.
23 Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active 
Crohn’s disease with onercept (recombinant human soluble p55 tumor ne‑
crosis factor receptor): results of a randomized, open‑label, pilot study. Ali‑
ment Pharmacol Ther. 2003; 17: 185‑192.
24 Osterman MT, Lichtenstein GR. Current and future anti‑TNF therapy 
for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007; 
10: 195‑207.
25 Stak WA, Mann SD, Roy AJ, et al. Randomised controlled trial 
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cet. 1997; 349: 521‑524.
26 Sandborn WJ, Feagan BG, Radford‑Smith G, et al. CDP571, a hu‑
manised monoclonal antibody to tumour necrosis factor alpha, for mod‑
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trolled trial. Gut. 2004; 53: 1485‑1493.
27 Feagan BG, Sandborn WJ, Lichtenstein G, et al. CDP571, a humanized 
monoclonal antibody to tumour necrosis factor‑alpha, for steroid‑depen‑
dent Crohn’s disease: a randomized, double‑blind, placebo‑controlled trial. 
Aliment Pharmacol Ther. 2006; 1: 617‑628.
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controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s dis‑
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29 Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a month‑
ly subcutaneously administered Fc‑free anti‑TNF alpha, improves health‑re‑
lated quality of life in patients with moderate to severe Crohn’s disease. Int 
J Colorectal Dis. 2008; 23: 289‑296.
30 Schreiber S, Khaliq‑Kareemi M, Lawrance IC, et al. Maintenance ther‑
apy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007; 19: 
296‑298.
31 Blick SK, Curran MP. Certolizumab pegol: in Crohn’s disease. Bio Drugs. 
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2008; 58: 964‑975.
Namely, treatment of UC patients involved epi‑
dermal growth factor in the form of rectal infu‑
sions, while treatment of CD patients involved 
granulocyte colony stimulating factor and gran‑
ulocyte‑macrophage colony stimulating factor.
It should also be emphasized that IBD treat‑
ment involves also other therapeutic options such 
as gene therapy, hematopoietic stem cell trans‑
plantation or leukapheresis.
summAry Conventional CD and UC therapy 
quite commonly does not bring satisfactory re‑
sults; therefore, inter est in new treatment meth‑
ods has been growing recently. Bio logical therapy 
is a highly promising prospect, since it enables 
to discontinue the use of glucocorticosteroids 
and immunosuppressives or their dose reduc‑
tion, shortens the hospitalization period, allows 
to avoid surgical treatment, extends the remission 
period and improves the patient’s quality of life.
A multidirectional character of bio logical 
therapy requires further clinical trials to dem‑
onstrate which treatment method is most ben‑
eficial in long‑term follow‑up. Currently, using 
anti‑TNF‑α monoclonal antibodies seems most 
promising.
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